

A Comparison of Pharmaceutical Research and Development Spending

For more information on the study:

Box L40
Standard Life Centre
333 Laurier Avenue West
Suite 1400
Ottawa, Ontario
K1P 1C1

by fax: (613) 952-7626

by email at:
sdupont@pmprb-cepmb.gc.ca

As announced in our Research Agenda in January 2002 and subsequent communications, we are conducting work on a study comparing R&D spending by the brand name pharmaceutical industry in Canada and other major industrialized countries. This work is meant to update and extend an earlier PMPRB study, *A Comparison of Pharmaceutical Research and Development Spending*, Study Series S-9709, released in October 1997. It is hoped that the report will be completed this fall.

Measures to be updated include:

- total R&D pharmaceutical expenditure
- R&D expenditure by type of activity
- ratios of pharmaceutical R&D to sales
- pharmaceutical R&D per capita
- the distribution of pharmaceutical R&D and sales across countries.

It is expected the study will rely on three principal data sources: R&D and sales figures reported to the PMPRB by individual manufacturers, information reported publicly by the national pharmaceutical industry associations and data collected and reported by the OECD.

The PMPRB has prepared a document outlining the proposed methodology for this study. This document is available on our website under Publications; Study Series; *A Comparison of Pharmaceutical Research and Development Spending 2002 — Methodology*. Anyone wishing to provide comments should do so in writing by August 30. ■